# OnCo record capitello-291 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/capitello-291/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "capitello-291", "NCT04305496" ;
  schema:name "CAPItello-291"@en ;
  schema:description "Adding the AKT inhibitor capivasertib to fulvestrant doubled progression-free time, especially in tumours with PI3K-pathway mutations."@en ;
  schema:url <https://onco.cc/trials/capitello-291/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04305496> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2020-04-16" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/pi3k-akt-mtor-inhibitors/> ;
  onco:targets <https://onco.cc/targets/akt/>, <https://onco.cc/targets/pik3ca/> ;
  onco:drugs <https://onco.cc/drugs/capivasertib/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> ;
  onco:people <https://onco.cc/people/nicholas-turner/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-capitello-291-nejm-2023/> .